These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Red blood cell calcium homeostasis in patients with end-stage renal disease. Gafter U; Malachi T; Barak H; Djaldetti M; Levi J J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934 [TBL] [Abstract][Full Text] [Related]
24. Metabolomic profiling of uremic solutes in CKD patients. Toyohara T; Akiyama Y; Suzuki T; Takeuchi Y; Mishima E; Tanemoto M; Momose A; Toki N; Sato H; Nakayama M; Hozawa A; Tsuji I; Ito S; Soga T; Abe T Hypertens Res; 2010 Sep; 33(9):944-52. PubMed ID: 20613759 [TBL] [Abstract][Full Text] [Related]
25. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Wang X; Shapiro JI Nat Rev Nephrol; 2019 Mar; 15(3):159-175. PubMed ID: 30664681 [TBL] [Abstract][Full Text] [Related]
26. Nephrology: main advances in the last 40 years. Locatelli F; Del Vecchio L; Pozzoni P; Manzoni C J Nephrol; 2006; 19(1):6-11. PubMed ID: 16523419 [TBL] [Abstract][Full Text] [Related]
29. Out of control: accelerated aging in uremia. Kooman JP; Broers NJ; Usvyat L; Thijssen S; van der Sande FM; Cornelis T; Levin NW; Leunissen KM; Kotanko P Nephrol Dial Transplant; 2013 Jan; 28(1):48-54. PubMed ID: 23139404 [TBL] [Abstract][Full Text] [Related]
30. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Marrs JC; Saseen JJ Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359 [TBL] [Abstract][Full Text] [Related]
31. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence. Thomas G; Jaber BL Semin Dial; 2009; 22(6):610-4. PubMed ID: 20017830 [TBL] [Abstract][Full Text] [Related]
32. Chronic kidney disease and cardiovascular risk. Yerram P; Karuparthi PR; Hesemann L; Horst J; Whaley-Connell A J Am Soc Hypertens; 2007; 1(3):178-84. PubMed ID: 20409850 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity. Chillon JM; Mozar A; Six I; Maizel J; Bugnicourt JM; Kamel S; Slama M; Brazier M; Massy ZA Ann Pharm Fr; 2009 Jul; 67(4):234-40. PubMed ID: 19596096 [TBL] [Abstract][Full Text] [Related]
38. Coagulation disorders in uremia. Molino D; De Lucia D; Gaspare De Santo N Semin Nephrol; 2006 Jan; 26(1):46-51. PubMed ID: 16412826 [TBL] [Abstract][Full Text] [Related]